Los Angeles Capital Management LLC Purchases Shares of 16,702 Prothena Corporation plc $PRTA

Los Angeles Capital Management LLC acquired a new position in Prothena Corporation plc (NASDAQ:PRTA) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund acquired 16,702 shares of the biotechnology company’s stock, valued at approximately $101,000.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Prospera Financial Services Inc bought a new stake in Prothena in the second quarter worth $61,000. Corton Capital Inc. bought a new stake in shares of Prothena in the 2nd quarter worth about $85,000. Mogy Joel R Investment Counsel Inc. purchased a new stake in shares of Prothena during the 2nd quarter valued at about $126,000. Purkiss Capital Advisors LLC lifted its holdings in shares of Prothena by 15.1% in the 2nd quarter. Purkiss Capital Advisors LLC now owns 24,904 shares of the biotechnology company’s stock valued at $151,000 after acquiring an additional 3,275 shares during the last quarter. Finally, Chicago Partners Investment Group LLC lifted its holdings in shares of Prothena by 29.6% in the 1st quarter. Chicago Partners Investment Group LLC now owns 14,512 shares of the biotechnology company’s stock valued at $180,000 after acquiring an additional 3,315 shares during the last quarter. 97.08% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on PRTA shares. Wall Street Zen raised Prothena from a “sell” rating to a “hold” rating in a research note on Saturday, November 8th. Royal Bank Of Canada boosted their target price on Prothena from $10.00 to $11.00 and gave the company a “sector perform” rating in a research report on Friday, November 7th. Chardan Capital restated a “buy” rating and issued a $18.00 price target on shares of Prothena in a research report on Thursday, August 28th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Prothena in a research note on Monday. Finally, UBS Group set a $36.00 target price on shares of Prothena in a research note on Tuesday, October 28th. Four analysts have rated the stock with a Buy rating, four have issued a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $25.78.

Prothena Stock Up 1.1%

Shares of Prothena stock opened at $10.36 on Wednesday. The stock’s fifty day moving average is $9.77 and its two-hundred day moving average is $7.85. Prothena Corporation plc has a 52 week low of $4.32 and a 52 week high of $17.66. The company has a market capitalization of $557.68 million, a PE ratio of -1.84 and a beta of -0.09.

Prothena (NASDAQ:PRTA) last released its earnings results on Thursday, November 6th. The biotechnology company reported ($0.67) earnings per share for the quarter, missing the consensus estimate of ($0.60) by ($0.07). The business had revenue of $2.42 million for the quarter, compared to the consensus estimate of $6.64 million. Prothena had a negative return on equity of 62.17% and a negative net margin of 2,929.30%. As a group, research analysts anticipate that Prothena Corporation plc will post -4.04 earnings per share for the current year.

Prothena Company Profile

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson’s disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer’s disease.